Natalizumab for Multiple Sclerosis
Top Cited Papers
- 21 June 2007
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (25) , 2622-2629
- https://doi.org/10.1056/nejmct071462
Abstract
A 30-year-old woman with relapsing–remitting multiple sclerosis presents for consideration of treatment with natalizumab after several first-line treatments have failed. Natalizumab has been shown to reduce the rates of relapse and disease progression in multiple sclerosis. However, use of this agent is restricted because of the risk of progressive multifocal leukoencephalopathy, a serious central nervous system disorder.Keywords
This publication has 46 references indexed in Scilit:
- Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosisNeurology, 2007
- Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathyCurrent Opinion in Neurology, 2006
- Costs and quality of life of patients with multiple sclerosis in EuropeJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Published by Wiley ,2006
- Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.Cleveland Clinic Journal of Medicine, 2006
- Natalizumab and PMLNature Neuroscience, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Deletion of α4 Integrins from Adult Hematopoietic Cells Reveals Roles in Homeostasis, Regeneration, and HomingMolecular and Cellular Biology, 2003
- Effects of VLA‐4 antagonists in rat whole embryo cultureTeratology, 2002